

Supplementary Materials

Ceratinadins E and F, new bromotyrosine alkaloids from an Okinawan marine sponge *Pseudoceratina* sp.

Shin-ichiro Kurimoto¹, Taito Ohno¹, Rei Hokari², Aki Ishiyama², Masato Iwatsuki², Satoshi Ōmura², Jun'ichi Kobayashi³ and Takaaki Kubota^{1,*}

¹Showa Pharmaceutical University, 3-3165 Higashi-Tamagawagakuen, Machida, Tokyo 194-8543, Japan.

²Kitasato Institute for Life Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan.

³Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo 060-0812, Japan.

Table of Contents:

Figure S1. ESIMS spectrum (positive ion mode) of ceratinadin E (**1**).

Figure S2. Expanded ESIMS spectrum (positive ion mode) of ceratinadin E (**1**).

Figure S3. HRESIMS data (positive ion mode) of ceratinadin E (**1**).

Figure S4. ¹H NMR spectrum of ceratinadin E (**1**) in CD₃OD (600 MHz).

Figure S5. ¹³C NMR spectrum of ceratinadin E (**1**) in CD₃OD (150 MHz).

Figure S6. ¹H-¹H COSY spectrum of ceratinadin E (**1**) in CD₃OD (600 MHz).

Figure S7. HSQC spectrum of ceratinadin E (**1**) in CD₃OD (600 MHz).

Figure S8. HMBC spectrum of ceratinadin E (**1**) in CD₃OD (600 MHz).

Figure S9. ECD spectrum of ceratinadin E (**1**) in CH₃OH.

Figure S10. ESIMS spectrum (positive ion mode) of ceratinadin F (**2**).

Figure S11. Expanded ESIMS spectrum (positive ion mode) of ceratinadin F (**2**).

Figure S12. HRESIMS data (positive ion mode) of ceratinadin F (**2**).

Figure S13. ¹H NMR spectrum of ceratinadin F (**2**) in CD₃OD (600 MHz).

Figure S14. ¹³C NMR spectrum of ceratinadin F (**2**) in CD₃OD (150 MHz).

Figure S15. ¹H-¹H COSY spectrum of ceratinadin F (**2**) in CD₃OD (600 MHz).

Figure S16. HSQC spectrum of ceratinadin F (**2**) in CD₃OD (600 MHz).

Figure S17. HMBC spectrum of ceratinadin F (**2**) in CD₃OD (600 MHz).

Figure S18. ECD spectrum of ceratinadin F (**2**) in CH₃OH.

Figure S1. ESIMS spectrum (positive ion mode) of ceratinadin E (**1**).




Figure S2. Expanded ESIMS spectrum (positive ion mode) of ceratinadin E (**1**).




Figure S3. HRESIMS (positive) data of ceratinadin E (**1**).

<i>m/z</i>	Intensity	Theo. Mass	Delta (mmu)	Composition	RDB equiv.
1139.80628	184575.00	1139.80722	-0.94	$^{12}\text{C}_{35}^1\text{H}_{42}^{79}\text{Br}_3^{81}\text{Br}_3^{14}\text{N}_5^{16}\text{O}_8$	14.5

Figure S4. ^1H NMR spectrum of ceratinadin E (**1**) in CD_3OD (600 MHz).




Figure S5. ^{13}C NMR spectrum of ceratinadin E (**1**) in CD_3OD (150 MHz).




Figure S6. ^1H - ^1H COSY spectrum of ceratinadin E (**1**) in CD_3OD (600 MHz).




Figure S7. HSQC spectrum of ceratinadin E (**1**) in CD₃OD (600 MHz).




Figure S8. HMBC spectrum of ceratinadin E (**1**) in CD₃OD (600 MHz).




Figure S9. ECD spectrum of ceratinadin E (**1**) in CH₃OH.




Figure S10. ESIMS spectrum (positive ion mode) of ceratinadin F (**2**).




Figure S11. Expanded ESIMS spectrum (positive ion mode) of ceratinadin F (**2**).




Figure S12. HRESIMS (positive) data of ceratinadin F (**2**).

<i>m/z</i>	Intensity	Theo. Mass	Delta (mmu)	Composition	RDB equiv.
1531.76647	508623.19	1531.76303	3.43	$^{12}\text{C}_{48}^{1}\text{H}_{58}^{79}\text{Br}_4^{81}\text{Br}_4^{14}\text{N}_7^{16}\text{O}_{10}$	19.5

Figure S13. ^1H NMR spectrum of ceratinadin F (**2**) in CD_3OD (600 MHz).




Figure S14. ^{13}C NMR spectrum of ceratinadin F (**2**) in CD_3OD (150 MHz).




Figure S15. ^1H - ^1H COSY spectrum of ceratinadin F (**2**) in CD_3OD (600 MHz).




Figure S16. HSQC spectrum of ceratinadin F (**2**) in CD₃OD (600 MHz).




Figure S17. HMBC spectrum of ceratinadin F (**2**) in CD₃OD (600 MHz).




Figure S18. ECD spectrum of ceratinadin F (**2**) in CH₃OH.

